MSI-H

Clinical trials for MSI-H explained in plain language.

Never miss a new study

Get alerted when new MSI-H trials appear

Sign up with your email to follow new studies for MSI-H, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug duo aims to outperform standard care in Hard-to-Treat stomach cancer

Disease control Recruiting now

This phase 3 study compares a new two-drug immunotherapy (botensilimab + balstilimab) against the current standard treatment (chemotherapy plus nivolumab) in people with advanced or metastatic stomach or esophageal cancer that has a specific genetic feature (MSI-H/dMMR). The goal…

Matched conditions: MSI-H

Phase: PHASE3 • Sponsor: Centre Leon Berard • Aim: Disease control

Last updated May 07, 2026 18:38 UTC

MSI-H

Get alerted when new MSI-H trials appear

New drug duo aims to outperform standard care in Hard-to-Treat stomach cancer